Biological Treatment Approaches for Degenerative Disk Disease: A Literature Review of In Vivo Animal and Clinical Data

Yu Moriguchi1 Marjan Alimi1 Thamina Khair1 George Manolarakis1 Connor Berlin1 Lawrence J. Bonassar2 Roger Härtl1

1 Weill Cornell Brain and Spine Center, Department of Neurological Surgery, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, New York, United States
2 Department of Biomedical Engineering, Cornell University, Ithaca, New York, United States

Abstract

Study Design Literature review.

Objective Degenerative disk disease (DDD) has a negative impact on quality of life and is a major cause of morbidity worldwide. There has been a growing interest in the biological repair of DDD by both researchers and clinicians alike. To generate an overview of the recent progress in reparative strategies for the treatment of DDD highlighting their promises and limitations, a comprehensive review of the current literature was performed elucidating data from in vivo animal and clinical studies.

Methods Articles and abstracts available in electronic databases of PubMed, Web of Science, and Google Scholar as of December 2014 were reviewed. Additionally, data from unpublished, ongoing clinical trials was retrieved from clinicaltrials.gov and available abstracts from research forums. Data was extracted from the most recent in vivo animal or clinical studies involving any of the following: (1) treatment with biomolecules, cells, or tissue-engineered constructs and (2) annulus fibrosus repair.

Results Seventy-five articles met the inclusion criteria for review. Among these, 17 studies involved humans; 37, small quadrupeds; and 21, large quadrupeds. Findings from all treatments employed demonstrated improvement either in regenerative capacity or in pain attenuation, with the exception of one clinical study.

Conclusion Published clinical studies on cell therapy have reported encouraging results in the treatment of DDD and resultant back pain. We expect new data to emerge in the near future as treatments for DDD continue to evolve in parallel to our greater understanding of disk health and pathology.

Introduction

Occurring in 40% of individuals younger than 30 and in more than 90% of those older than 50 years of age,1,2 intervertebral disk (IVD) degeneration is a commonly diagnosed disorder that can lead to nerve compression and chronic back pain. Though pharmacologic and physiotherapeutic treatments relieve early symptoms, surgical intervention is eventually required in nearly 4 million patients worldwide.3 Spinal fusion surgery, most commonly performed in degenerative
disk cases, presents risks for pseudarthrosis and adjacent segment disease, resulting in higher rates of reoperation in patients.\(^4,5\) Prosthetic total disk replacement (TDR) devices, developed to maintain segmental mobility, are an alternative to fusion surgery. However, recent studies have shown that not only spinal fusion but also TDR alters spine biomechanics leading to adjacent segment disease.\(^5,6\) Hence, it remains controversial whether the theoretical advantage of TDR truly translates to clinical or radiologic superiority over fusion surgery.\(^5,6\) Current treatment options to disk degeneration, both conservative and surgical, fail to treat the underlying etiology; the degenerated disk remains unrepaired.

To overcome the limitations of available treatments, biological repair has emerged as a feasible way to treating pathologic disk segments. Strategies utilized in biological IVD repair are specific to the stage of degeneration and can be classified into three categories: biomolecular therapy, cell therapy, and tissue-engineered IVD construction (\(\text{Fig. 1}\)).\(^7-9\) Early degenerated disks with sufficient populations of viable cells is treated with biomolecules, such as recombinant genes or proteins (\(\text{Fig. 2}\)). These agents can enhance selective protein expression to decrease catabolic or increase anabolic cascades, favoring extracellular matrix (ECM) regeneration. Midstage degeneration, characterized by less active and rapidly disappearing viable cells, is treated with cell implantations to meet the increased demand of the disk. When the disk structure and function are severely compromised, reaching terminal stage degeneration, implantation of tissue-engineered disklike constructs is the most potent option for reconstruction of the disk segment. Each treatment modality utilized can target specific structures of the IVD. The IVD is an intricate complex composed of diverse but interrelated tissues: the central gelatinous and highly hydrated nucleus pulposus (NP), the stiffly composed annulus fibrosus (AF) surrounding the NP, and the cartilaginous end plates that connect these tissues to the vertebral bodies provide ample nutrition. Given that degeneration is a multifaceted process that involves the NP, AF, and end plate, one or all components can be targets of potential biological repair.

For many years, NP tissue has been the principal focus of disk repair in early to midstage degeneration, but interest has recently turned to the AF as a more practical target.\(^10\) Strategies targeted at NP, primarily through transannular approaches, compromise the AF tissue.\(^11\) Additionally, an annular defect is the underlying etiology for patients with lumbar disk hernia; diskectomies to remove herniated disks can unveil annular defects, which are often overlooked and left untreated by surgeons due to the limited reparative options. Persistent annular defects are related to reherniation and progressive disk degeneration postdiskectomy.\(^12,13\) Hence, annular repair is an emerging but significant facet in the treatment of degenerative disk disease (DDD). In the present study, we review in vivo animal and clinical studies of biological disk repair. Integrating degenerative stage-specific and IVD component-specific therapy helps elucidate a multifaceted treatment module for disk degeneration. An analysis of the varying research, previous and current, in degenerated disk repair offers greater insight into potential clinical applicability, propelling their transition from bench to bedside.
Methods

A comprehensive search of the literature was performed. Full publications and abstracts available in the electronic databases of PubMed, Web of Science, and Google Scholar as of December 2014 were reviewed. Additionally, data from unpublished, ongoing clinical trials was retrieved from clinicaltrials.gov and available abstracts from research forums. After the initial search, the results were reviewed, duplicates were excluded, and only the relevant studies were included. The primary inclusion criterion was the presence of in vivo and/or clinical results on disk regeneration. The secondary inclusion criterion was the ability to be categorized into one of the following categories: (1) biomolecular therapy, (2) cell-based therapy, (3) tissue-engineered IVD construction, (4) AF repair, (5) published and ongoing clinical studies. After article selection, we extracted the following outcome measures for in vivo animal studies: disk height based on X-ray, signal intensities and degenerative grade based on magnetic resonance imaging (MRI), histologic assessment of reparative tissue, proteoglycan content, and biomechanical functionality. For clinical studies, we extracted questionnaire-based subjective assessment on preexisting pain and physical function in addition to radiologic outcome measures.

In Vivo Animal Studies

Biomolecular Treatment

A defining compositional change in degenerated disks is the gradual decline of NP water content emanating from the loss of proteoglycan and collagen. The loss of swelling pressure in the NP is followed by the loss of mechanical tension in the AF collagen fibers, resulting in abnormal loading of the spine. These alterations often lead to segmental instability with the development of neck or back pain and narrowing of the spinal canal, which may induce neurologic symptoms. In early degeneration, the disk undergoes an imbalance of anabolic and catabolic factors that leads to ECM degradation. Biomolecules such as recombinant proteins and genes can regenerate expression of target molecules through the increase in anabolic or decrease in catabolic factor production, thus facilitating ECM synthesis. The following section will review recent in vivo studies on biomolecules used to treat disk degeneration\(^1\)\(^{-40}\) (Table 1).

Protein Injection

Protein solutions directly injected into disks can stimulate cell growth or anabolic responses that may reverse disk degeneration. Since the demonstration of the disk's responsiveness to exogenous growth factors in an ex vivo organ culture system,\(^41\) the various proteins capable of modulating cell growth, differentiation, and ECM synthesis have shown promise in treating degenerative disk disease (DDD). Bone morphogenic proteins (BMPs) such as BMP2, BMP7 also known as osteogenic protein 1 (OP-1), and BMP14 or growth differentiation factor-5 (GDF-5), as well as other members of transforming growth factor (TGF)-\(\beta\) superfamily such as TGF-\(\beta 1\) or TGF-\(\beta 3\) have induced bone and cartilage formation. Their application has been well studied not only in cases of spinal arthrodesis but also disk regeneration.\(^1\)^\(^{-20,22,31}\) In a single in vivo rabbit study by An et al, intradiscal OP-1 injection induced an increase in proteoglycan (PG) content of NP at 2 weeks and disk height at 8 weeks\(^1\)\(^{,19}\); the treatment has now segued into clinical trials. Protein injection, though promising, is challenged by the short duration of its therapeutic effect, which may be overcome with the development of slow-release carriers or gene-based delivery systems.

Gene Therapy

Gene therapy induces modification of intradiscal gene expression for prolonged effect on degenerated disks. The genes of interest are delivered through either viral (mostly adenovirus) or nonviral vectors, which are then either
Table 1 List of in vivo study of biomolecular treatment

| Species | Model | Molecules          | Dose                   | Outcome                                                                 | Reference |
|---------|-------|--------------------|------------------------|-------------------------------------------------------------------------|-----------|
| Rat     | Compression | IGF-1, GDF-5, TGF-β, bFGF | IGF-1: 8 ng/8 μL/disk, GDF-5: 8 ng/8 μL/disk, TGF-β: 1.6 ng/8 μL/disk, bFGF: 8 ng/8 μL/disk | GDF-5 and TGF-β aid in expansion of inner annular fibrochondrocytes into the nucleus | 16        |
| Rat     | Compression | BMP-7 (OP-1) | 0.2 μg/μL/disk | OP-1 stimulates anabolic response characterized by the restoration of normal disk morphology | 22        |
| Rabbit  | Normal | BMP-7 (OP-1) | 2 ng/10 μL/disk | Increase in disk height | 14        |
| Rabbit  | Chemonucleolysis by C-ABC | OP-1 | 100 μL/10 μL/disk | Increase in disk height and PG content | 15        |
| Rabbit  | Needle puncture | BMP-7 (OP-1) | 100 μg/10 μL/disk | Improvement in disk height and MRI findings | 17        |
| Rabbit  | Needle puncture | GDF-5 | 1,100 ng, 1,100 μg/10 μL/disk | Increase in disk height | 18        |
| Rabbit  | Needle puncture | OP-1 | 100 μg/10 μL/disk | Increase in disk height and PG content of the NP | 19        |
| Rabbit  | Annular tear 5 × 7 mm | BMP-2 | 100 μL/10 μL/disk | Exacerbated degeneration | 20        |
| Rabbit  | Nucleotomy | PRP | 20 μL PRP + microsphere/disk | Less degeneration, more PG | 21        |
| Rabbit  | Nucleotomy | PRP | 20 μL PRP + microsphere/disk | Improvement in disk height and water content | 23        |
| Rabbit  | Annular puncture | PRP-releasate | 20 μL/disk | Better X-ray and MRIs | 25        |
| Sheep   | Annular incision | BMP 13 | 300 μg/70 μL saline | BMP 13 prevents loss of hydration | 24        |
| Gene therapy | Degenerative model induced by unbalanced dynamic and static force | Lentiviral CHOP shRNA | 1 × 10⁶ PFU/2 μL/disk | Significant decrease of apoptotic incidence in cells treated with CHOP shRNA at 7 wk | 30        |
| Rat     | Normal | Plasmid DNA mixed with microbubbles | 2 μg/2 μL/disk | Reported genes were expressed up to 24 wk | 28        |
| Rabbit  | Normal | Ad/CMV-hTGFβ1 | 6 × 10⁶ PFU/15 μL/disk | Leads to double proteoglycan synthesis | 26        |
| Rabbit  | Normal | Ad-LMP1 | 1 × 10⁷ PFU/10 μL/disk | LMP1 overexpression increases PG, BMP-2, and BMP-7 | 27        |
| Rabbit  | Annular puncture | ADAMTS5 siRNA oligonucleotide | 10 μg/10 μL/disk | Improvement in MRI and histological scores | 29        |
| Rabbit  | Annulotomy | AAV2-BMP2 or-TIMP1 | 6 × 10⁶ virus particles/15 μL/disk | AAV-BMP2 and -TIMP1 delayed degeneration | 31        |
| Rabbit  | Postannulotomy | Ad-Sox9 | 1 × 10⁸ PFU/10 μL/disk | AdSox9 helped retain chondrocytic appearance, cellular morphology, and ECM at 5 wk | 32        |

Abbreviations: AAV2-BMP2, adeno-associated virus serotype 2 vectors expressing bone morphogenetic protein 2; Ad/CMV-hTGFβ1, adenovirus/cytomegalovirus vector expressing human transforming growth factor-beta 1; ADAMTS5, disintegrin and metalloproteinase with thrombospondin motifs 5; Ad-LMP1, adenoviral vectors expressing Lim Mineralization Protein-1; Ad-Sox9, adenoviral vectors expressing Sox9; bFGF, basic fibroblastic growth factor; BMP, bone morphogenic protein; C-ABC, chondroitinase-ABC; CHOP, C/EBP homologous protein; ECM, extracellular matrix; siRNA, small interfering RNA; GDF-5, growth differentiation factor-5; IGF-1, insulin-like growth factor-1; OP-1, osteogenic protein 1; PFU, plaque forming units; PRP, platelet-rich plasma; shRNA, small hairpin RNA; TGF-β, transforming growth factor β; TIMP1, tissue inhibitor of metalloproteinase-1.

Note: Animal species and model of disk degeneration are shown. *Normal* means normal healthy disks were treated without any induction of degeneration. Biomolecules employed and doses are also shown. Outcomes are briefly summarized with reference information.
directly injected into live tissue (in vivo gene therapy) or transduced/transfected into cells in vitro prior to in vivo transplantation (ex vivo gene therapy or cell-based gene therapy).\textsuperscript{42} In one of the earliest in vivo studies in a rabbit model, when the NP cells were transduced with TGF-β1-expressing adenovirus vector, proteoglycan synthesis increased by 100\% in the treated tissue.\textsuperscript{26} Since then, a variety of proteins have surfaced as promising targets for gene therapy including upstream proteins such as LIM mineralization protein-1 (LMP-1), which regulates BMP-2 and BMP-7, ECM degrading enzymes (disintegrin and metalloproteinase with thrombospondin motifs 5), their inhibitors (tissue inhibitor of metalloproteinase-1), chondrocyte-specific transcription factors (SRY-box 9, Sox9), and apoptosis inducers (C/EBP homologous protein).\textsuperscript{26–32} Though gene therapy is advantageous in its sustained effect, the inherent risk of viral gene delivery systems becoming infectious or immunogenic has relayed interest toward nonviral gene delivery systems. Microbubble-enhanced ultrasound gene therapy and injection of small interfering RNA have been shown to achieve long-standing transgene expression in IVD cells in vivo.\textsuperscript{28,29} However, nonviral gene delivery systems are curtailed by low transfection efficiency, which must be addressed to enhance their clinical applicability. The feasibility of ex vivo gene therapy, which reduces the risks of infection and immunogenicity and plays an important role in the future of tissue-engineering technology, has been explored in a few studies.\textsuperscript{43,44}

**Platelet-Rich Plasma**
Platelet-rich plasma (PRP), an autologous blood product produced by the centrifugation of whole blood, offers an attractive cocktail of proteins for the treatment of degenerative disks due to its high concentration of platelets. Upon activation, these platelets release a variety of multifunctional growth factors such as platelet-derived growth factor, insulin-like growth factor, TGF-β1, vascular endothelial growth factor, and basic fibroblastic growth factor. When used in early onset disk degeneration, PRP can better enhance disk hydration.\textsuperscript{45} Various PRP technologies have emerged to retard the degenerative cascade, including a gelatinous hydrogel scaffold impregnated with PRP and soluble releasate derived from activated PRP.\textsuperscript{21,23,25} The in vivo efficacy of PRP in yielding better disk height and hydration has facilitated its transition to ongoing clinical trials.

**Cell Therapy**
Biomolecules are of limited efficacy in disks with higher grades of degeneration, as the number of cells responsive to injected genes and proteins declines with the progression of degeneration.\textsuperscript{46} Cell therapy is the optimal treatment strategy in midstage degeneration, characterized by a decreased number of cells in the tissue; several in vivo studies reported the efficacy of using a vast array of cell sources (\textit{Table 2}).\textsuperscript{46–75}

**Differentiated Cells Such as Disk-relevant Cells and Articular Chondrocytes**
Implanted differentiated disk chondrocytes, which can produce demanded ECM components such as proteoglycan and collagen type II and I under hypoxia and nutrient stress, can meet the increased cellular and metabolic demands of the disk.\textsuperscript{76} Accumulating evidences in an array of animal models demonstrate that autologous or allogeneic disk cells, when transplanted, survive and engraft in the disk, yielding reduction of matrix degradation and recovery of disk height and MRI intensities (\textit{– Table 2}). In fact, the pioneering preclinical study in an injured canine model established that NP disk chondrocyte implantation contributes to ECM regeneration, retarding further disk degeneration.\textsuperscript{54} However favorable, disk cell transplantation poses several drawbacks: (1) donor site morbidity; (2) difficulty expanding cells in vitro while maintaining cell phenotype; (3) paucity of allograft donor tissue; and (4) issues of immunocompatibility and disease transmission. Similar to differentiated disk cells, cultured articular chondrocytes are a well-established nondisk cell source in regenerative medicine.\textsuperscript{77} Their easy extraction from non-weight-bearing parts of the knee and capacity to produce NP-like ECM when transplanted in vivo makes autologous or allogenic articular chondrocytes a safe and feasible cell source in IVD regeneration.\textsuperscript{48,67} Furthermore, potential immune evasion by juvenile articular chondrocytes supports their applicability in allogenic cell transplantation.

**Stem Cells**
The multipotent mesenchymal stem cells (MSCs) present in adult bone marrow or adipose tissue can replicate as undifferentiated cells, then differentiate into lineages of mesenchymal tissue: bone, cartilage, fat, tendon, muscle, and marrow stroma.\textsuperscript{78} These somatic stem cells are potentially an ideal option for disk repair due to their accessibility and ability to differentiate along a chondrogenic lineage and produce the required proteoglycan and collagen for the disk ECM. The feasibility of MSCs to facilitate disk repair has been substantiated. Yet, it remains controversial whether differentiated cells or stem cells are superior in their regenerative capacity of disk morphology. A porcine study comparing the utility of different cell sources found that committed articular chondrocytes are better suited for use in disk repair than MSCs due to their aptness for survival in the ischemic disk microenvironment.\textsuperscript{67} Interestingly, a comparative rabbit study found that MSC transplantation can serve as an ideal substitute for differentiated chondrocytes of disk NP owing to better accessibility with equivalent regenerative potential.\textsuperscript{68} Studies assessing the combination of both cells demonstrated that in vitro coculture or coimplantation yields better in vivo performance of the implanted cells.\textsuperscript{57,69} Nonetheless, pluripotent embryonic and induced pluripotent stem cells,\textsuperscript{79–81} unlike the lower potent MSCs, have unlimited proliferative and differentiative capacities, which can be strategically exploited in cell-based disk repair. Sheikh et al extracted murine embryonic stem cells (ESCs) and differentiated them into chondroprogenitor cells; upon implantation into rabbit injured disks, these cells induced notochordal cell formation at the site of injury sans xenograft-associated immune responses.\textsuperscript{59} Unstable in vitro differentiation into desired cell lineages and in vivo risks of tumor formation are still major obstacles in the use of ESCs and induced pluripotent stem
| Species    | Model                  | Cell type                                      | Dose                                           | Outcome                                                                                                                   | Reference |
|-----------|------------------------|-----------------------------------------------|------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|-----------|
| Mouse     | Postannular injury     | Allogenic bone marrow MSCs                    | BMSCs $1.0 \times 10^3$                        | ECM augmented in NP via autonomous differentiation and stimulation of endogenous cells at 12 wk                          | 61        |
| Mouse     | Annular puncture       | Multipotent stem cells derived from human umbilical cord blood | $1.0 \times 10^2$ cells intradiscally, $1.0 \times 10^5$ cells intravenously | Unlike intradiscal injection, intravenous injection did not preserve the IVD architecture nor disk height at 14 wk          | 71        |
| Sand rat  | Diskectomy             | Autologous disk cells                         | $1.0 \times 10^4$ cells/5 µL/2-mm³ Gel-foam (Pfizer, New York, NY, United States) | Implanted disk engrafted with the host disk for up to 8 mo                                                                | 46        |
| Rat       | Normal                 | Bone marrow MSCs                              | $5.0 \times 10^2/50$ µL hyaluronan gels        | MSCs maintained viability and proliferated over 28 d                                                                      | 49        |
| Rat       | Postannular puncture   | Human bone marrow MSCs                        | $1.0 \times 10^6/15$ µL                       | Human MSCs survived for 2 wk posttransplantation, increasing disk height and MRI intensity                                 | 62        |
| Rat       | Postannular puncture   | Adipose-derived MSCs                          | $1.0 \times 10^6/50$ µL                       | Disks maintained disk height and restored MRI signal intensity                                                            | 63        |
| Rat       | Nucleotomy             | Coculture of NP cells and MSCs                | $2.5 \times 10^3$ cells (25% NP cells and 75% MSCs) | Bilaminar coculture pellet of NP cells and MSCs outperformed solely NP cells or MSCs at 5 wk                               | 69,70     |
| Rabbit    | Nucleotomy             | Allogeneic NP cells                           | $5.0 \times 10^4$ cells/20 µL                  | Histology indicated delayed degeneration at 16 wk                                                                       | 47        |
| Rabbit    | Nucleotomy             | Autologous articular chondrocytes             | $2.0 \times 10^6/150$ µL                      | Chondrocytes survived and produced hyaline-like cartilage at 6 mo                                                        | 48        |
| Rabbit    | Normal                 | Allogeneic bone marrow MSCs                   | $1.0 \times 10^5$ cells                       | MSCs survived and enhanced PG synthesis                                                                                 | 50        |
| Rabbit    | Postnucleotomy         | Autologous MSCs                               | $4.0 \times 10^7/40$ µL Atecollogen (CELLGEN, Koken, Tokyo, Japan) | Improved disk height, MRIs, and histology at 48 wk                                                                        | 51–53     |
| Rabbit    | Postannular injury     | Autologous bone marrow MSCs                   | $1.0 \times 10^7/25$ µL                       | Injection of MSCs significantly increased PG synthesis in severely degenerated disks at 16 wk                             | 56        |
| Rabbit    | Normal                 | Allogeneic MSCs                               | $1.0 \times 10^7/15$ µL                       | Injected cells engrafted into inner annulus fibrous at 24 wk                                                            | 57        |
| Rabbit    | Postpuncture           | Xenogeneic derivatives of embryonic stem cells| $1.0 \times 10^6$ cells/20 µL                  | New notochordal cells observed; no immune response elicited                                                             | 59        |
| Rabbit    | Nucleotomy             | Allogenic synovial MSCs                       | $1.0 \times 10^7$ cells/100 µL PBS            | Implanted cells labeled with Dil or GFP detected at 24 wk; disk height and MRI signal intensity were maintained        | 64        |
### Table 2 (Continued)

| Species | Model          | Cell type                                   | Dose                              | Outcome                                                                                     | Reference |
|---------|----------------|---------------------------------------------|-----------------------------------|--------------------------------------------------------------------------------------------|-----------|
| Rabbit  | Compression    | Allogenic bone marrow MSCs                  | 0.08 mL of 1.0 × 10^6 cells/mL     | Combination of MSC injection and distraction led to better disk height and histology at 8 wk | 66        |
| Rabbit  | Postnucleotomy | Autologous NP cells and allogeneic MSCs     | 1.0 × 10^6/20 μL                  | Both NP cells and MSCs better maintained disk height and GAG content at 16 wk               | 68        |
| Canine  | Postnucleotomy | Disk cells                                  | 6.0 × 10^6 cells/1 mL/disk         | Disk remained viable, produced ECM, better maintained disk height                            | 54, 55    |
| Canine  | Postnucleotomy | Autologous MSCs                             | 1.0 × 10^6/mL stem cells           | MSCs led to better disk height, MRI, and histology grading at 12 wk                         | 58        |
| Canine  | Postnucleotomy | Bone marrow MSCs                            | 10^5, 10^6, 10^7 cells             | The disk treated with 106 MSCs had more viable cells than 105 and less apoptotic cells than 105 cells at 12 wk | 65        |
| Porcine | Postnucleotomy | Human MSCs                                  | 0.5 × 10^6/hydrogel carrier        | Implanted cells survived and differentiated into disklike cells at 6 mo                     | 60        |
| Porcine | Nucleotomy     | Allogeneic juvenile chondrocytes and MSCs   | 7–10 × 10^6/0.5–75 mL fibrin carrier | JC outperformed MSCs in proteoglycan synthesis at 12 mo                                       | 67        |

Abbreviations: BMSC, bone marrow stem cell; ECM, extracellular matrix; GAG, glycosaminoglycan; IVD, intervertebral disk; JC, juvenile chondrocyte, MRI, magnetic resonance imaging; MSC, mesenchymal stem cell; NP, nucleus pulposus; PBS, phosphate-buffered saline; PG, proteoglycan.

Note: Animal species and model of disk degeneration are shown. "Normal" means normal healthy disks were treated without any induction of degeneration. Cells employed and dose are also shown. Outcomes are briefly summarized with reference information.
cells. However, if these issues are overcome, both cells may offer unparalleled promise in degenerative disk repair.

**Tissue-Engineering Strategy**

Since Langer and Vacanti pioneered the multidisciplinary field of tissue engineering in 1993, much effort has been directed toward the construction of functional substitutes for damaged disk tissues. Tissue engineering originally consisted of three and more recently four components: scaffolds, cells, growth factors, and physical conditioning using electrical or mechanical stimuli (Fig. 3). Because extensive loss of matrix and structural damages are exhibited in advanced stages of disk degeneration, the development of biocompatible and biomimetic scaffolding materials based on engineering innovation can facilitate the recovery of native biological and biomechanical functionality. Numerous studies have assessed tissue-engineered components as well as whole-disk constructs of the disk in vivo (Table 3).

**Scaffold Development**

Numerous scaffold materials that mimic the mechanical and biochemical properties of the native NP have been studied including alginate, silk-fibrin/hyaluronic acid composites, Atelocollagen, synthetic polymers, and collagen 2/hyaluronan/chondroitin-6-sulfate composites. Hyaluronic acid, a native NP ECM component, has been extensively studied in vivo. In a rabbit study, resorbable cell-free implants made of a polyglycolic acid felt, hyaluronic acid, and serum induced disk regeneration after discectomy, resulting in improved disk hydration and disk height 6 months after microdiscectomy. Cells are frequently used in conjunction with biomimicking materials to encourage de novo ECM production. Ganey et al found that adipose-derived stem cells contributed to recovery of T2 intensity and disk height in a canine disk injury model. Synthetic polymers such as polyglycolic acid or poly (L-lactic-co-glycolic acid) have also been used to construct cell-laden tissue-engineered composites either solely or in combination with hydrogels.

**Whole Disk Transplantation with Tissue-Engineered Construct**

Advanced tissue engineering enables whole IVD construction in vitro, which can be implanted in vivo through TDR. The current standard in whole IVD implantation involves NP and AF composites that replace the structurally damaged tissues of a severely degenerated disk. The first tissue-engineered whole IVD, implanted in vitro within the subcutaneous dorsum of athymic mice, comprised an NP cell-laden polyglycolic and polylactic acid (polyglycolic acid) and AF cell-laden alginate. Our group was the first to perform an in vivo implantation of anatomically correct whole tissue-engineered IVDs (TE-IVDs) in the athymic rat tail model; the implanted disks engrafted into the disk space for up to 6 months and exhibited analogous biological, biochemical, and biomechanical properties as the native disks (Fig. 4). To bring this innovation closer to clinical application, we recently performed TDR using TE-IVDs in the canine cervical spine, characterized by axial loading due to their upright neck, which most closely resembles that in humans. Our preliminary data with 1-month follow-up revealed that TE-IVDs when implanted successfully remained viable in the disk segment, engrafted to the host tissue, and partially maintained disk height. Nonetheless, the addition of growth factors or bioactive molecules can encourage de

**Fig. 3** Cell therapy and tissue engineering. Allograft transplant is the simplest biological disk repair; however, it has critical drawbacks such as limited availability of healthy donor disks and potential risk of disease transmission. Cells harvested from different sources can be expanded in vitro and transplanted in vivo in cell transplant for disk regeneration. Scaffolds can be combined with cells, and, if they have biomimicking properties, these treatments can be regarded as a part of tissue-engineering strategy, which traditionally included cells, scaffolds, growth, and factors, but recently included gene treatment and mechanical conditioning. Abbreviations: AC, articular chondrocytes; AF, annulus fibrosus cells; NP, nucleus pulposus cells.
| Species | Model | Construct                                                                 | Outcome                                                                                                                                                                                                 | Reference |
|---------|-------|----------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| Rat     | Subcutaneous implantation | TE-IVD composed of a NP cell-laden alginate surrounded by an AF cell-laden PGA/PLA | Biochemical markers of matrix synthesis, increasing over time, were similar to native tissue at 12 wk                                                                                                 | 84        |
| Rat     | Subcutaneous Implantation | Porous CII/HyA/CS                                                            | CII/HyA/CS scaffolds had satisfactory cyto-compatibility and histocompatibility, as well as low immunogenicity                                                                                           | 88        |
| Rat     | Subcutaneous implantation | Composite IVD consisting of demineralized bone matrix gelatin and CII/HyA/CS scaffolds seeded AF and NP cells | Implant, similar to native disk in morphology and histology, increased proteoglycan synthesis over 12 wk                                                                                               | 92        |
| Rat     | Total diskectomy | TE-IVD composed of a NP cell-laden alginate surrounded by an AF cell-laden collagen layer | TE-IVD maintained disk space height, produced de novo ECM, and integrated into the spine—yielding intact motion segment with dynamic mechanical properties similar to that of native IVD | 93        |
| Rat     | Subcutaneous implantation | $5.0 \times 10^6$ cells/mL in PPS containing polyethylene glycol/HA            | MPC/hydrogel composites formed cartilage-like tissue, well tolerated by the host                                                                                                                                 | 99        |
| Rabbit  | Laser diskectomy | $2.0 \times 10^6$ cells/Atelocollagen honeycomb-shaped scaffold | AF cells survived and produced hyaline-like cartilage in the disk at 12 wk                                                                                                                                 | 83        |
| Rabbit  | Microdiskectomy  | Cell-free implant composed of a PGA felt, HA, and allogenic serum            | Implantation of a cell-free PGA-HA implant immersed in serum after diskectomy improved disk hydration and preserved disk height 6 mo after surgery                                                                 | 86        |
| Rabbit  | Postnucleotomy | $2.0 \times 10^6$ bone marrow MSCs in 0.04 mL PFG-TGF-B1                     | MSCs-in-PFG-TGF-ß1 group had less degeneration and a slower decrease in disk height compared with both degenerative and acellular PFG-TGF-ß1 group                                                                 | 90        |
| Rabbit  | Nucleotomy    | Allogenic NP cell-seeded CII/HyA/CS tri-copolymer construct                  | Viability of allografted NP cells, extracellular matrix deposition, and disk height maintenance; restoration of T2 MRI signal intensity observed at 24 wk                                                                 | 94        |
| Rabbit  | Postpuncture  | $5.0 \times 10^3$ allogenic bone marrow MSCs/10 μL hydrogel                | MSCs suppressed collagen I in NP; reduced collagen aggregation, and maintained proper fibrillar properties and function                                                                                      | 101       |
| Rabbit  | Postnucleotomy | $1.0 \times 10^6$ human NP cell line infected with HNPSV-5 in Atelocollagen  | Deceleration of disk degeneration was evident after HNPSV-5 transplantation as shown by disk height and histologic examination at 24 wk                                                                        | 102       |
| Canine  | Total diskectomy | Cell-allograft IVD composites made of allograft and NP cells, with in vitro transduced with r(AAV)-hTERT | The hTERT-loaded NP cells intervention could effectively resist the degeneration of the allogenic transplanted IVD at 12 wk                                                                                   | 43        |
Table 3 (Continued)

| Species     | Model                        | Construct                                                                 | Outcome                                                                 | Reference |
|-------------|------------------------------|---------------------------------------------------------------------------|-------------------------------------------------------------------------|-----------|
| Canine      | Postnucleotomy               | ADRC in HA carrier                                                        | Disk that received ADRC produced matrix and resembled native disk in morphology at 12 mo | 87        |
| Canine      | Nucleotomy                   | Cell-scaffold composite made of three-dimensional porous PLGA scaffolds and NP cells | Disk height, segmental stability, and T2-weighted MRI signal intensity were well preserved at 12 wk | 89        |
| Porcine     | Nucleotomy                   | Cell-scaffold composite made of NP cells and injectable hyaluronan-derived polymeric substitute material HYADD (1.0 x 10^5 cells/mL) | Injected disks had a central NP-like region similar to the normal disk biconvex structure and viable chondrocytes forming matrix like that of normal disk at 6 wk | 85        |
| Porcine     | Post annular injury          | 1.25 x 10^5 autologous MSCs/mL in either Hydrogel Photofix (Zimmer Biologics, Inc., Austin, TX, United States) or HA (Zimmer Biologics, Inc.) | Stem cells in hydrogel treatment had significantly higher T2 MRI intensities and lower degeneration grade at 24 wk than hydrogel alone treatment | 95        |
| Porcine     | Partial nucleotomy           | 5.0 x 10^5 autologous bone marrow MSCs transduced with retrovirus encoding luciferase in 1 mL hyaluronan-enhanced albumin hydrogel | In vivo 3-d analysis showed persistent metabolically active implanted cells in the disk | 100       |
| Goat        | Postdisk injury              | 2.5 x 10^5 allogenic bone marrow stromal cells/10 μL PBS + 30 μL chondroitin sulfate-based hydrogel | Significant increase in NP proteoglycan accumulation at 6 mo | 96        |
| Sheep       | Total disectomy              | Noncrystalline polylactide copolymer interbody cages filled with 1.0 x 10^6 allogenic MPC-laden Gelfoam sponge (Pfizer, New York, NY, United States) formulated with the chondrogenic agent PPS | Biodegradable cage-contained MPCs in combination with PPS produced cartilaginous tissue at 3 mo | 91        |
| Sheep       | Post-chondroitinase-ABC injection | 4.0 x 10^6 or 0.5 x 10^6 human MPCs suspended in HA | High-dose injection improved histopathology scores at 3 mo, while low dose at 6 mo | 97        |
| Sheep       | Nucleotomy                   | Allogenic or autologous disk cells (0.4–2.0 x 10^6 cells/0.5–1 mL hydrogel) in hydrogel containing HA and mal- eoyl-albumin | Biological repair of traumatic damage occurs in sheep disks at 6 mo; hydrogel-supported disk cells may be beneficial | 98        |

Abbreviations: ADRC, autologous adipose tissue derived stem and regenerative cells; AF, annulus fibrosus; CI, type II collagen; CS, chondroitin-6-sulfate; HA, hyaluronic acid; HNPSV-5, recombinant SV40 adenovirus vector; hTERT, human telomerase reverse transcriptase; HyA, hyalurionate; HYADD, an amide of hyaluronan-derived polymeric substitute materials; IVD, intervertebral disk; MPC, mesenchymal precursor cell; MRI, magnetic resonance imaging; MSCs, mesenchymal stem cells; NP, nucleus pulposus; PBS, phosphate-buffered saline; PFG-TGF-β1, fibrin glue containing 10 μg/mL TGF-β1; PGA, polyglycolic acid; PLA, polyglycolic acid; PLGA, poly(lactic-co-glycolic acid); PPS, pentosan polysulfate; (rAAV)-hTERT, recombinant adenoassociated virus vector-mediated hTERT gene; TE-IVD, tissue-engineered IVD; TGF-β1, transforming growth factor-β1.

Note: Animal species and model of disk degeneration are shown. "Normal" means normal healthy disks were treated without any induction of degeneration. Constructs employed and dose are also shown. Outcomes are briefly summarized with reference information.
novo ECM deposition. Goldschlager et al demonstrated that adult allogeneic mesenchymal progenitor cells formulated with a chondrogenic agent such as pentosan polysulfate could synthesize a cartilaginous matrix when implanted into a biodegradable carrier and cage and over time might serve as a bioactive interbody spacer following anterior cervical diskectomy.

Furthermore, the integration of tissue engineering and gene therapy has been attempted by a group from China that developed a tissue-engineered IVD using an allogenic disk transduced with human telomerase reverse transcriptase (hTERT) gene within its NP cells. When implanted in a canine model, the hTERT-loaded NP cells manifested enhanced antidegenerative effect compared with the unloaded NP cell.

Such constructions of whole disk implants, the most ambitious therapeutic strategy yet, are met with extensive biological and functional challenges in vivo. Yet, the progressing field of tissue engineering continues to yield promising modifications to meet the higher demands of implanted disks.

**Annular Repair**

Previous studies of intervertebral disk repair, which aim to halt, delay, or reverse intervertebral disk degeneration, were primarily focused on NP regeneration.33–38 However, a majority of these strategies are delivered through a punctured AF, which even upon modest injury can generate a degenerative cascade within the disk affecting IVD biomechanics, cellularity, and biosynthesis.109–112 Annular defects can emerge not only from needle punctures through the AF to reach the NP but also from the early process of intervertebral disk degeneration. Given the sensitivity of the AF, lesions from the NP treatment can provoke further degeneration, inducing leakage of the delivered material and eventual failure of the regenerative treatment. In fact, one retrospective study with 10 years’ follow-up found that diskography performed with a small needle puncture accelerated disk degeneration, rate of same-side disk herniation, and changes to the end plate.12

Another study demonstrated that injecting MSCs through the AF into the NP led to cell leakage and augmented osteophyte formation.13 Combining an injectable NP regenerative strategy with a sealant that repairs annular defects is the optimal strategy to circumvent leakage of implanted cells or material while enhancing therapeutic outcome. Previous approaches to annular repair have involved mechanical treatments such as suturing and annuloplasty devices, which failed to improve annular healing strength in long-term clinical trials.113–115 Although several NP regenerative studies and a few in vitro AF studies provide critical insight on the reparative process within the AF tissue,24,53,83,96,116 there is a very limited number of in vivo studies focusing primarily on annular repair.107,117–122 Current efforts in the biological treatment for in vivo AF repair include either development of injectable material in conjunction with biologics such as biomolecules/cells or construction of rigid implants derived from synthetic polymer or biological tissue (Table 4). In fact, our group has successfully demonstrated the in vivo efficacy of riboflavin cross-linked high-density collagen gels to facilitate annular repair in a needle-punctured rat-tail model through preservation of NP size, hydration, and prevention of further degeneration (Fig. 5).107 In another large animal study...
conducted by Oehme et al, injected mesenchymal progenitor cells combined with the chondrogenic agent pentosan polysulfate maintained disk height, disk morphology, and NP proteoglycan content post-microdiskectomy in a sheep model. Despite the few studies dedicated to annular repair, more attention is now being paid to this field given its enhancement of even NP-targeted therapy.

Table 4 List of published annular repair studies

| Species | Model | Treatment | Outcome | Reference |
|---------|-------|-----------|---------|-----------|
| Rat     | Degradation tests with subcutaneous implantation | Fibrin-genipin adhesives hydrogel (Fib-Gen) | 60% of Fib-Gen remained at 8 wk and nearly all resorbed at 16 wk; kinetics show better in vivo longevity compared with fibrin | 121 |
| Rat     | Needle puncture | Injection of cross-linked HDC gels | Cross-linked HDC capable of repairing annular defects most likely due to enhanced stiffness of HDC at 5 wk | 107 |
| Porcine | Needle puncture | Injection of Gelfoam (Pfizer, New York, NY, United States), platinum coil, bone cement, and tissue glue | Injection of Gelfoam better improved integrity of punctured disk than the other three to potentially prevent recurrent disk herniation at 2 mo | 118 |
| Sheep   | Box annulotomy | Patch and plug with SIS and titanium bone screw | SIS-based treatment led to better maintenance of hydration and intradiscal pressure at 26 wk after annulotomy | 119 |
| Sheep   | Box annulotomy | Triphase AF implant consisting two outer phases of absorbable polyglycolic acid and a centric phase of a non-absorbable PVDF mesh | Implant-treated disks had more reparative tissue, but contrast media leakage tests under provocative pressure did not show the difference between groups | 122 |
| Sheep   | Microdiskectomy | Allogenic MPCs + PPS embedded in a gelatin/fibrin scaffold | Disks treated with MPC + PPS showed higher PG content than the untreated or ones treated with solely scaffold at 6 mo | 120 |

Abbreviations: AF, annulus fibrosus; HDC, high-density collagen; MPC, mesenchymal progenitor cell; PPS, pentosan polysulphate; PVDF, polyvinylidene fluoride; SIS, small intestinal submucosa.

Note: Animal species and model of disk degeneration are shown. "Normal" means normal healthy disks treated without any induction of degeneration. Treatments employed are also shown. Outcomes are briefly summarized with reference information.

Clinical Studies

Published Clinical Trials
To date, only few clinical trials targeting IVD repair or regeneration have been published (-Table 5). In 2002, a multicenter prospective, randomized, controlled, nonblinded EuroDISC study comparing the safety and efficacy of autologous disk chondrocyte transplant implanted 12 weeks after diskectomy concluded that the implant attenuated low back pain and preserved disk height over a 2-year span.55,125,131 The commercially available chondrotransplant DISC is now available for autologous disk chondrocyte transplant. More recently, a variety of stem cells entered the spotlight due to their differentiative and proliferative capacities. The first stem cell–based clinical study published in the field of disk regeneration was focused on hematopoietic stem cells, although patients’ discogenic back pain did not improve after 1 year.123

MSCs derived from bone marrow are the most well-studied cells in regenerative medicine due to their accessibility through minimally invasive procedures and expandability in ex vivo conditions. Two studies demonstrated the feasibility of autologous bone marrow MSCs to facilitate disk hydration based on follow-up MRIs over 1 year.127,128 Orozco et al demonstrated rapid improvement of pain and disability despite unrecovered disk height.128 In another prospective case series using noncultured bone marrow concentrate as a form of autologous point-of-care biologics, patients with either cervical or lumbar DDD receiving a single injection experienced attenuated discogenic pain and improved function for up to 12 months.

Due to their similar biological profile to disk chondrocytes and potential immunoprivileged property, allogeneic juvenile articular chondrocytes are another promising cell source.
In a prospective cohort study, Coric et al demonstrated that NuQu (ISTO Technologies, Inc., St. Louis, Missouri, United States), an injectable percutaneous fibrin-based delivery of juvenile chondrocytes, attenuated otherwise medically refractory low back pain (pain that does not respond to conservative therapy). A class II study has recently been completed. Despite these studies’ promising results, further investigation with a prospective, randomized, double-blinded, placebo-controlled study is necessary to make cell transplantation a valid therapeutic option for DDD.

Although there is no clinical study of tissue-engineering material, efforts have been made to create functional substitutes for NP. Among many clinical studies focusing on NP replacement, a single-center, nonrandomized, prospective feasibility study was undertaken to investigate whether the use of NuCore Injectable Nucleus hydrogel (Spine Wave, Inc., Shelton, Connecticut, United States) post-microdiskectomy prevented early disk collapse to potentially slow the degenerative cascade of the spinal segment over time. A group in China was the first to bring a whole allogeneic IVD implantation, inclusive of all three-disk components, to a clinical setting. Though the implant successfully integrated into the host tissue, over the course of 5 years, degeneration was eventually observed. Despite preserving motion in the treated segment, the clinical advantages of allogeneic IVDs are undermined by the limited availability of healthy donor disks and potential disease transmission. De novo tissue-engineered constructs utilizing terminally differentiated cells, yet to reach clinical trials, can potentially overcome limitations of allogeneic implants and yield favorable outcomes.
Several ongoing clinical trials aiming at disk repair have yet to publish their findings (Table 6). The first ever biologic treatments with human recombinant growth factors rhBMP-7 (OP-1) and rhGDF-5 (human growth/differentiation factor-5) are currently undergoing clinical trial. PRP or soluble releasate isolated from PRP, both with concentrated growth factors from activated platelets, have been clinically studied in autologous injection models. Akeda et al first demonstrated the feasibility of intradiscal PRP-releasate injection in reducing low back pain in patients with DDD. More recently, a prospective, randomized controlled study assessing the efficacy of intradiscal PRP injections in discogenic mediated low back pain has already shown improvements in pain and function in patients as early as 8 weeks, which was sustained for up to 1 year. A 2-year follow-up is currently under process. Mesenchymal lineage adult stem cells (MLCs) (Mesoblast, Melbourne, Australia), the commercially available cell line of in vitro expanded mesenchymal precursor cells (MPCs), is also under clinical trial. The randomized, placebo-controlled phase 2 trial of 100 patients with DDD-induced chronic low back pain already appears promising. Among patients receiving a single injection of either 6 or 18 million mesenchymal progenitor cells, 44 and 42%, respectively, reached target criteria for treatment end point (50% reduction in pain, 15-point improvement in function, and no further treatment needed) at both 6 and 12 months; only 13% of patients administered placebo had the same outcome. A few other clinical studies using autologous disk chondrocytes, allogeneic juvenile chondrocytes, and autologous and allogeneic MSCs derived from bone marrow or adipose tissues are also underway. One such cell-based study is using activated NP cells through in vitro coculture with MSCs to target moderately degenerated disks.

Table 5 List of published clinical studies

| Trial treatment | No. of patients | Study design | Follow-up (mo) | Outcome | Reference |
|-----------------|-----------------|--------------|----------------|---------|-----------|
| Autologous hematopoietic stem cell injection | 10 | Case series | 12 | No patients reported any improvement in their discogenic back pain | 123 |
| Total disk replacement with allogeneic IVD | 5 | Case series | 60 | Allograft engrafted disk space without apparent immunoreaction; all minus one disk preserved range of motion | 124 |
| Autologous disk chondrocyte transplantation (EuroDisc) | 28 | Control study | 24 | ADCT with disectomy shows more pronounced decrease in OPDQ than disectomy alone | 125,131 |
| Injectable biomimetic nucleus hydrogel | 14 | Case series | 24 | Significant improvement in leg and back pain after microdisectomy | 126 |
| Autologous bone marrow mesenchymal cell injection | 2 | Case series | 24 | Both patients showed improvements in the vacuum phenomenon as well as signal intensity of T2-weighted MRIs | 127 |
| Autologous bone marrow mesenchymal cell injection | 10 | Case series | 12 | Rapid improvement of pain and disability; disk height was not recovered, but disk hydration was significantly elevated | 128 |
| Allogeneic juvenile chondrocytes injection (NuQu; ISTO Technologies, Inc., St. Louis, Missouri, United States) | 15 | Case series | 12 | ODI, NRS, SF-36 improved from baseline; 89% of the patients showed improvement on MRI | 129 |
| Injection of autologous bone marrow concentrate cells | 26 | Case series | 12 | Statistically significant improvement in pain scores and impairment was demonstrated; most dramatic improvement seen in patients with higher CFU-F concentrations; rehydration of the disks observed in 8 of 20 patients | 130 |

Abbreviations: ADCT, autologous disk chondrocyte transplant; CFU-F, colony-forming unit fibroblast; IVD, intervertebral disk; ODI, Oswestry Disability Index; OPDQ, Oswestry Low Back Pain Disability Questionnaire; MRI, magnetic resonance imaging; NRS, Numeric Rating Scale; SF-36, Short Form 36. Note: Treatments, patient number, study design, follow-up are shown. Outcomes are briefly summarized with reference information.
### Table 6: List of unpublished ongoing clinical trials

| Trial                                                                 | No. of patients | Study design                  | Follow-up (mo) | Intervention                                                                                                           | Assessment                                                                 | Status            | Reference |
|----------------------------------------------------------------------|-----------------|--------------------------------|----------------|-----------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|-------------------|-----------|
| Safety and efficacy of juvenile chondrocytes injected into the lumbar disk to treat low back pain | 44              | Double-blind, randomized control, phase 2 | 24             | Single administration NuQu (ISTO Technologies, Inc., St. Louis, Missouri, United States) (allogeneic chondrocyte in fibrin carrier) and a placebo of normal saline | Subject-reported outcomes of pain and disability, health-related quality of life, and subject satisfaction with treatment | Phase II done     | 133       |
| MPCs (Mesoblast, Melbourne, Australia) in subjects with chronic discogenic lumbar back pain | 100             | Double-blind, randomized control, phase 2 | 36             | Single dose of either high or low MPCs in a hyaluronic acid carrier and a placebo of either normal saline or hyaluronic acid | MRI, VAS scores, physical exam, and clinical laboratory tests | Phase II done     | 134       |
| Allogeneic MSCs for DDD                                              | 24              | Double-blind, randomized, phase 1, 2 | 12             | Single intradiscal transplantation of MSC and sham-treated comparator with drug mepivacaine                          | VAS, Oswestry Disability Index, and life quality evolution questionnaires; quantitative MRI for disk fluid content | Ongoing           | 135       |
| Autologous adipose tissue derived mesenchymal stem cells in lumbar IVD degeneration | 8               | Nonrandomized, open label      | 6              | Injection of autologous adipose-derived MSCs into lumbar IVD at dose $4 \times 10^7$ cells/1 mL                         | MRI, VAS scores, physical examination, clinical laboratory tests         | Ongoing           | 136       |
| Adipose tissue-derived stem cells suspended in PRP for DDD          | 100             | Nonrandomized, open label      | 12             | Intradiscal administration of PRP suspended adipose tissue-derived stem cells, obtained from adipose tissue of the abdomen | VAS scores, Oswestry Disability Index, and low back pain questionnaire    | Ongoing           | 137       |
| Intradiscal rhGDF-5 (BMP14) for early stage lumbar DDD              | 38              | Double-blind, randomized, phase 1, 2 | 36             | Single injection of rhGDF-5 into a degenerating lumbar spinal disk                                                  | MRI                                                                       | Ongoing           | 138       |
| Lumbar intradiscal PRP injections                                    | 72; PRP: 48, control: 24 | Double-blind, randomized controlled study | 6              | Single injection of PRP to the patients with concordant discogenic                                                 | NRS, modified NASS outcome questionnaire, FRI, SF-36                    | Ongoing           | 139       |

(Continued)
Table 6 (Continued)

| Trial                                                                 | No. of patients | Study design | Follow-up (mo) | Intervention                                                                 | Assessment            | Status   | Reference |
|----------------------------------------------------------------------|-----------------|--------------|----------------|-----------------------------------------------------------------------------|-----------------------|----------|-----------|
| Intradiscal injection of PRP-releasate for the treatment of lumbar disk degeneration | 6               | Case series | 6              | Injection of the soluble releasate isolated form clotted PRP into symptomatic degenerated disks | VAS, RDQ, MRI         | Ongoing  | 140       |
| Injection of activated NP cells to moderately degenerated disks adjacent to the fused segment | 10              | Case series | 36             | Single injection of autologous NP cells harvested from resected disk during fusion surgery; activated by in vitro coculture with bone marrow MSCs, and percutaneously injected into adjacent segment | Side effect assessment, blood tests, MRIs | Ongoing  | 141       |

Abbreviations: BMP14, bone morphogenic protein 14; DDD, degenerative disk disease; FRI, functional rating index; IVD, intervertebral disk; MPC, mesenchymal precursor cell, also termed as mesenchymal lineage adult stem cells (MLCs); MRI, magnetic resonance imaging; MSC, mesenchymal stem cells; NASS, North American Spine Society; NP, nucleus pulposus; NRS, Numeric Rating Scale; PRP, platelet-rich plasma; RDQ, Roland-Morris Disability Questionnaire; rhGDF-5, recombinant human growth/differentiation factor-5; SF-36, Short Form 36; VAS, visual analog scale.

Note: Treatments, patient number, study design, follow-up period, and current status are shown. Intervention and assessment are also briefly summarized.
adjacent to the fused segment. Ultimately, the data emerging from these on-going clinical trials will reinforce findings from published studies and provide new insight for future biological disk repair.

Discussion

The current article is a review study of in vivo experimental and clinical data on treatment approaches for degenerative disk disease, which comprise biomolecular therapy, cell therapy, tissue-engineered construction, and annular repair. A plethora of animal studies have offered critical insight into the regenerative capacity of new IVD therapies due to the similarity in biological and mechanical properties between animals and humans. Yet, the transition from animal to human application is met with challenges. In animal studies, both histologic sections for proteoglycan content and biomechanical testing can be easily evaluated, but these outcome measures are extremely rare in clinical studies. Rather, clinical studies are primarily focused on questionnaire-based subjective assessment on pain and physical function, parameters that are out of scope in animal studies with the exception of two that have developed unique pain assessments in animals.\textsuperscript{143,144} Due to these model-based limitations, there is a paucity of studies elucidating direct relation between pain relief and underlying biological repair. Additionally, the animal models may provide mechanistic clues (e.g., genes or signaling factors) to phenotypic manifestations in humans, but complications in comparison arise due to presence of notochordal cells not found in human adults.\textsuperscript{9,145} Notochordal cells of NP tissue are present only during the first decade of human life and then are replaced with chondrocyte-like cells, of which the origin has yet to be elucidated. Although cows, horses, and chondrodystrophic dogs such as beagles demonstrate similar age-related changes to humans, mice, rats, rabbits, pigs, cats, and nonchondrodystrophic dogs such as mongrels, they are reported to retain notochordal cells past skeletal maturity, which may enhance intrinsic cellular repair.\textsuperscript{145} Therefore, results observed in animal models must be carefully translated prior to clinical application.

Within the last decade, there has been significant progress in the field of biological treatments for DDD, despite the few clinical studies published. Injection of biomolecules, such as proteins or genes, and cells can attenuate the degenerative cascade at early to midstages of disease progression. Due to their minimal invasiveness to patients, biomolecular therapy and cellular therapy are easier to maneuver onto clinical application than tissue engineering. In fact, the first clinical trials with rhBMP-7 (OP-1) and BMP-14 (GDF-5) are now underway. Cell therapy, the most exploited therapeutic strategy in both animal and human application, has already been fruitful in treating discogenic pain among patients with nonterminal degeneration. Yet, because all these injectable strategies employ transannular approaches, integration with a treatment for resulting annular defects should be utilized for enhanced clinical outcome.

Annular repair has only recently entered the spotlight due to its potential to spatially retain remnant NP, but merits consideration in its restoration of disk integrity and functionality. TE-IVD, the multicompartiment disk analogues using cells and biomaterials, can autonomously regenerate disk morphology and functionality postimplantation. A variety of in vitro studies have indicated the promise of using disk constructs for TDR,\textsuperscript{146–149} the most advanced therapeutic strategy for terminally degenerated disks. However, only two translational studies have demonstrated the in vivo efficacy of TE-IVDs for TDR; more are to come in the near future. Though tissue engineering is progressing in its development, TDR using TE-IVDs remains challenging in both implantation and function. Implanting biological constructs as functional disk substitutes requires invasive procedures with increased patient risks; hence, there are greater surgical hurdles to overcome to reach clinical trial with TE-IVDs than with alternative strategies. One preferable option to deliver the implant into the designated site is the use of minimally invasive spine surgery, which can significantly curb surgical damage to surrounding healthy tissue and provide the implant with additional mechanical support based on the premise that minimally invasive surgery causes a significantly lesser increase in range of motion compared with traditional open procedures.\textsuperscript{150} As evidenced by prosthetic TDR,\textsuperscript{151} displacement of the implant is a complication when positioned in a stand-alone fashion, predominantly due to the weight-bearing human spine yielding severe axial loading. Therefore, the experimental results obtained from quadrupedal animal studies, even when promising, must be interpreted with caution before transitioning the interventions onto humans. Furthermore, the construction of implants that remain viable within a mechanically and trophically inhospitable environment remains technically difficult. However, the combined use of implant with a fixator inducing distraction may enhance the in vivo performance by reducing the risk of implant displacement, stabilizing the implanted segment, and improving the nutrition supply.\textsuperscript{66}

In addition to the severe mechanical loading, all therapeutic approaches must combat the disk’s poor nutritional supply, diffused from the blood vessels of the vertebral body through the cartilaginous end plate. Despite being one of three IVD components and implicated in disk degeneration, the end plate has hardly been factored into regenerative strategies.\textsuperscript{149} In fact, the role of nutrition, critical in the long-term durability of implanted biological treatments, has been largely overlooked. A study by Guehring et al demonstrated that distraction of the disk segment improves hydration, enhances ECM gene expression, and increases protein-expressing gel.\textsuperscript{152} As demonstrated by Hee et al, distraction facilitates the regeneration of the ECM in both cartilaginous and osseous end plates as well as the recovery of vascular channels, which are vital to the nutritional supply.\textsuperscript{153} The authors corroborated this result through their finding that axial distraction using an external fixator enhanced the regenerative capability of cell injection therapy, based on the hypothesis that individually both a distracted segment and cell injection can stimulate disk repair.\textsuperscript{66} Hence, although the implantation of therapeutic biologics can independently regenerate the degenerated disk to some extent, a holistic
treatment with host environmental conditioning that combats the severe mechanical loading and poor nutritional supply is required for optimal and durable clinical outcomes.

Research in the treatment of DDD is continually evolving. Yet, there is a limited understanding of healthy IVD cell phenotype and adaptation in development and maturity, which is paralleled in the limited understanding of degenerative disease pathogenesis and progression. Although the treatment interventions currently being studied in the laboratory and those already applied to patients offer some remedial outcome, there has yet to be an established intervention that offers sustained disk protection, repair, and regeneration. The future of research in the field of disk degeneration will therefore rely on elucidating the differences in the biological features between a healthy and pathologic disk, which may offer insight into optimizing current treatments or the development of more novel treatments. Most innovations in animal models have shown significant promise, although only a few have transitioned onto clinical settings demonstrating their efficacy. Biomolecular and cellular treatments, the only therapeutics undergoing clinical trials, have shown remarkable progress already as determined by the available published and nonpublished data. Tissue engineering and annular repair, on the other hand, are still in the preclinical stage but offer great potential to close the gap between the current treatment attempts and successful disk repair and replacement. The future of human applications with biomolecular and cell-based interventions, combined with tissue engineering, offers exciting prospects in the treatment of DDD.

Disclosures
Yu Moriguchi: none
Marjan Alimi: none
Thamina Khair: none
George Manolarakis: none
Connor Berlin: none
Lawrence J. Bonassar: none
Roger Härtl: Consultant (Brainlab AG, Lanx, Inc., Depuy-Synthes, AO foundation); Research funding (Baxter)

References
1. Andersson GB. Epidemiological features of chronic low-back pain. Lancet 1999;354(9178):581–585
2. Cheung KM, Karpinnen J, Chan D, et al. Prevalence and pattern of lumbar magnetic resonance imaging changes in a population study of one thousand forty-three individuals. Spine (Phila Pa 1976) 2006;31(7):742–754
3. Chuo T, An HS, Akeda K, et al. Effects of growth differentiation factor-5 on the intervertebral disc—in vitro bovine study and in vivo rabbit disc degeneration model study. Spine (Phila Pa 1976) 2006;31(25):2909–2917
4. Côté P, Cassidy JD, Carroll LH, et al. The economic burden of low back pain and disability in Canada. CMAJ 2001;164(11):1633–1639
5. Kelly MP, Mok JM, Frisch RF, Tay BK. Adjacent segment motion after anterior cervical discectomy and fusion versus Prodisc-c cervical total disk arthroplasty: a randomized, controlled trial. Spine (Phila Pa 1976) 2011;36(15):1171–1179
6. Zhang Y, Chee A, Thonar EJ, An HS. Intervertebral disc repair by protein, gene, or cell injection: a framework for rehabilitation-focused biologics in the spine. PM R 2011;3(6, Suppl 1):S88–S94
7. Moriguchi Y, Ichikawa K, Matsumoto T, et al. Platelet-rich plasma and bone morphogenetic protein-2 in the treatment of degenerative intervertebral disc disease: a randomized controlled trial. PM R 2013;5:78–83
8. Walsh AJ, Bradford DS, Lotz JC. In vivo growth factor treatment of degenerated intervertebral discs. Spine (Phila Pa 1976) 2004;29(2):156–163
9. An HS, Takegami K, Kamada H, et al. Intradiscal administration of osteogenic protein-1 increases intervertebral disc height and proteoglycan content in the nucleus pulposus in normal adolescent rabbits. Spine (Phila Pa 1976) 2005;30(1):25–31, discussion 31–32
10. Imai Y, Okuma M, An HS, et al. Restoration of disc height loss by recombinant human osteogenic protein-1 injection into intervertebral discs undergoing degeneration induced by an intradiscal injection of chondroitinase ABC. Spine (Phila Pa 1976) 2007;32(11):1179–1205
11. Vatala G, De Strobel F, Bernardini M, Denaro L, D’Avella D, Denaro V. The transpedicular approach for the study of intervertebral disc degeneration strategies: in vivo characterization. Eur Spine J 2013;22(Suppl 6):S972–S978
12. Carragee EJ, Han MY, Suen PW, Kim D. Clinical outcomes after lumbar discectomy for sciatica: the effects of fragment type and annular competence. J Bone Joint Surg Am 2003;85-A(1):102–108
13. Swart KR, Trost GR. Recurrent lumbar disc herniation. Neurosurg Focus 2003;15(3):E10
14. An HS, Takegami K, Kamada H, et al. Intradiscal administration of osteogenic protein-1 increases intervertebral disc height and proteoglycan content in the nucleus pulposus in normal adolescent rabbits. Spine (Phila Pa 1976) 2005;30(1):25–31, discussion 31–32
15. Imai Y, Okuma M, An HS, et al. Restoration of disc height loss by recombinant human osteogenic protein-1 injection into degenerated intervertebral discs. Spine (Phila Pa 1976) 2006;31(7):742–754
16. Walsh AJ, Bradford DS, Lotz JC. In vivo growth factor treatment of degenerated intervertebral discs. Spine (Phila Pa 1976) 2004;29(2):156–163
17. Masuda K, Imai Y, Okuma M, et al. Osteogenic protein-1 injection into a degenerated disc induces the restoration of disc height and structural changes in the rabbit anular puncture model. Spine (Phila Pa 1976) 2006;31(7):742–754
18. Walsh AJ, Bradford DS, Lotz JC. In vivo growth factor treatment of degenerated intervertebral discs. Spine (Phila Pa 1976) 2004;29(2):156–163
19. Moriguchi Y, Ichikawa K, Matsumoto T, et al. Platelet-rich plasma and bone morphogenetic protein-2 in the treatment of degenerative intervertebral disc disease: a randomized controlled trial. PM R 2013;5:78–83
20. Côté P, Cassidy JD, Carroll LH, et al. The economic burden of low back pain and disability in Canada. CMAJ 2001;164(11):1633–1639
21. Nague M, Ikeda T, Mikami Y, et al. Intradermal injections of osteogenic protein-1 restore the viscoelastic properties of degenerated intervertebral discs. Spine J 2006;6(6):S94–S98
22. Moriguchi Y, Ichikawa K, Matsumoto T, et al. Platelet-rich plasma and bone morphogenetic protein-2 in the treatment of degenerative intervertebral disc disease: a randomized controlled trial. PM R 2013;5:78–83
23. Côté P, Cassidy JD, Carroll LH, et al. The economic burden of low back pain and disability in Canada. CMAJ 2001;164(11):1633–1639
24. Wei A, Williams LA, Bhargav D, et al. BMP13 prevents the effects of annular injury in an ovine model. Int J Biol Sci 2009;5(5):388–396
25 Obata S, Akeda K, Imanishi T, et al. Effect of autologous platelet-rich plasma release on intervertebral disc degeneration in the rabbit anular puncture model: a preclinical study. Arthritis Res Ther 2012;14(6):R241
26 Nishida K, Kang JD, Gilbertson LG, et al. Modulation of the biologic activity of the rabbit intervertebral disc by gene therapy: an in vivo study of adenovirus-mediated transfer of the human transforming growth factor beta 1 encoding gene. Spine (Phila Pa 1976) 1999;24(23):2419–2425
27 Yoon ST, Park JS, Kim KS, et al. ISSLS prize winner: LMP-1 upregulates intervertebral disc cell production of proteoglycans and BMPs in vitro and in vivo. Spine (Phila Pa 1976) 2004;29(23):2603–2611
28 Nishida K, Doita M, Takada T, et al. Sustained transgene expression in intervertebral disc cells in vivo mediated by microbubble-enhanced ultrasound gene therapy. Spine (Phila Pa 1976) 2003;31(13):1415–1419
29 Seki S, Asanuma-Abe Y, Masuda K, et al. Effect of small interferon RNA (siRNA) for ADAMSS on intervertebral disc degeneration in the rabbit anular needle-puncture model. Arthritis Res Ther 2009;11(6):R166
30 Zhang YH, Zhao CQ, Jiang LS, Dai LY. Lentiviral shRNA silencing of CHOP inhibits apoptosis induced by cyclic stretch in rat annular cells and attenuates disc degeneration in the rats. Apoptosis 2011;16(6):594–605
31 Leckie SK, Bechara BP, Hartman RA, et al. Injection of AAV2-BMP2 and AAV2-TIMP1 into the nucleus pulposus slows the course of intervertebral disc degeneration in an in vivo rabbit model. Spine J 2012;12(1):7–20
32 Paul R, Haydon RC, Cheng H, et al. Potential use of Sox9 gene therapy for intervertebral degenerative disc disease. Spine (Phila Pa 1976) 2003;28(8):755–763
33 Masuda K, Oegema TR Jr, An HS. Growth factors and treatment of intervertebral disc degeneration. Spine (Phila Pa 1976) 2004;29(23):2757–2769
34 Bae WC, Masuda K. Emerging technologies for molecular therapy for intervertebral disc degeneration. Orthop Clin North Am 2011;42(4):585–601, ix
35 Sakai D, Grad S. Advancing the cellular and molecular therapy for intervertebral disc disease. Adv Drug Deliv Rev 2015;84:159–171
36 Wang SZ, Rui YF, Lu J, Wang C. Cell and molecular biology of intervertebral disc degeneration: current understanding and implications for potential therapeutic strategies. Cell Prolif 2014;47(5):381–390
37 Kepler CK, Anderson DG, Tannoury C, Ponnappan RK. Intervertebral disc degeneration and emerging biologic treatments. J Am Acad Orthop Surg 2011;19(9):543–553
38 Blanquer SB, Grijppra DW, Poot AA. Delivery systems for the treatment of degenerated intervertebral discs. Adv Drug Deliv Rev 2015;84:172–187
39 Mern DS, Beierfuß A, Thomé C, Hegewald AA. Enhancing human nucleus pulposus cells for biological treatment approaches of degenerative intervertebral disc diseases: a systematic review. J Tissue Eng Regen Med 2014;8(12):925–936
40 Hubert MG, Vadala G, Sowa G, Studer RK, Kang JD. Gene therapy for the treatment of degenerative disc disease. J Am Acad Orthop Surg 2008;16(6):312–319
41 Thompson JP, Oegema TR Jr, Bradford DS. Stimulation of mature canine intervertebral disc by growth factors. Spine (Phila Pa 1976) 1991;16(3):253–260
42 Woods BL, Vo N, Sowa G, Kang JD. Gene therapy for intervertebral disk degeneration. Orthop Clin North Am 2011;42(4):563–574, ix
43 Xin H, Zhang C, Wang D, et al. Tissue-engineered allograft intervertebral disc transplantation for the treatment of degenerative disc disease: experimental study in a beagle model. Tissue Eng Part A 2013;19(1–2):143–151
44 Leo BM, Li X, Balian G, Anderson DG. In vivo bioluminescent imaging of virus-mediated gene transfer and transduced cell transplantation in the intervertebral disc. Spine (Phila Pa 1976) 2004;29(8):838–844
45 Gullung GR, Woodall JW, Tucci MA, James J, Black DA, McGuire RA. Platelet-rich plasma effects on degenerative disc disease: analysis of histology and imaging in an animal model. Evid Based Spine Care J 2011;2(4):13–18
46 Gruber HE, Johnson TL, Leslie K, et al. Autologous intervertebral disc cell implantation: a model using Psammomys obesus, the sand rat. Spine (Phila Pa 1976) 2002;27(15):1626–1633
47 Okuma M, Mochida J, Nishimura K, Sakabe K, Seki K. Reinsertion of stimulated nucleus pulposus cells retards intervertebral disc degeneration: an in vitro and in vivo experimental study. J Orthop Res 2000;18(6):988–997
48 Gorencsek M, Jaksimovic C, Kregar-Velikonja N, et al. Nucleus pulposus repair with cultured autologous elastic cartilage derived chondrocytes. Cell Mol Biol Lett 2004;9(2):363–373
49 Crevsten G, Walsh AJ, Ananthakrishnan D, et al. Intervertebral disc cell therapy for regeneration: mesenchymal stem cell implantation in rat intervertebral discs. Ann Biomed Eng 2004;32(3):430–443
50 Zhang YG, Guo X, Xu P, Kang LL, Li J. Bone mesenchymal stem cells transplanted into rabbit intervertebral discs can increase proteoglycans. Clin Orthop Relat Res 2005;(430):219–226
51 Sakai D, Mochida J, Yamamoto Y, et al. Transplantation of mesenchymal stem cells embedded in Atelocollagen gel to the intervertebral disc: a potential therapeutic model for disc degeneration. Biomaterials 2003;24(20):3531–3541
52 Sakai D, Mochida J, Iwashina T, et al. Differentiation of mesenchymal stem cells transplanted to a rabbit degenerative disc model: potential and limitations for stem cell therapy in disc regeneration. Spine (Phila Pa 1976) 2005;30(21):2379–2387
53 Sakai D, Mochida J, Iwashina T, et al. Regenerative effects of transplanting mesenchymal stem cells embedded in Atelocollagen to the degenerated intervertebral disc. Biomaterials 2006;27(3):335–345
54 Ganey T, Libera J, Moos V, et al. Disc chondrocyte transplantation in a canine model: a treatment for degenerated or damaged intervertebral disc. Spine (Phila Pa 1976) 2003;28(23):2609–2620
55 Hohaus C, Ganey TM, Minkus Y, Meisel HJ. Cell transplantation in lumbar spine disc degeneration disease. Eur Spine J 2008;17(Suppl 4):492–503
56 Ho G, Leung VY, Cheung KM, Chan D. Effect of severity of intervertebral disc injury on mesenchymal stem cell-based regeneration. Connect Tissue Res 2008;49(1):15–21
57 Sobajima S, Vadala G, Shimer A, et al. Nucleus pulposus transplantation in the intervertebral disc. Spine (Phila Pa 1976) 2004;29(8):838–844
58 Hiyama A, Mochida J, Iwashina T, et al. Transplantation of mesenchymal stem cells in a canine disc degeneration model. J Orthop Res 2008;26(5):589–600
59 Sheikh H, Zakharian K, De La Torre RP, et al. In vivo intervertebral disc regeneration using stem cell-derived chondroprogenitors. J Neurosurg Spine 2009;10(3):265–272
60 Henriksson HB, Svankvist T, Jonsson M, et al. Transplantation of human mesenchymal stem cells into intervertebral discs in a xenogeneic porcine model. Spine (Phila Pa 1976) 2009;34(2):141–148
61 Yang F, Leung VY, Luk KD, Chan D, Cheung KM. Mesenchymal stem cells arrest intervertebral disc degeneration through chondrocytic differentiation and stimulation of endogenous cells. Mol Ther 2009;17(11):1959–1966
62 Jeong JH, Jin ES, Min JK, et al. Human mesenchymal stem cells implantation into the degenerated coccyygeal disc of the rat. Cytotechnology 2009;59(1):55–64
63 Jeong JH, Lee JH, Jin ES, Min JK, Jeon SR, Choi KH. Regeneration of intervertebral discs in a rat disc degeneration model by...
Biological Treatment Approaches for Degenerative Disk Disease

Moriguchi et al.

Langer R, Vacanti JP. Tissue engineering. Science 1993;260(5110):81

Takahashi K, Yamanaka S. Induction of pluripotent stem cells. Cell 2006;126(4):663–895

Pittenger MF, Mackay AM, Beck SC, et al. Multipotency of human mesenchymal stem cells. Science 1999;284(5411):143–147

Evans MJ, Kaufman MH. Establishment in culture of pluripotential cell lines from mouse embryos. Nature 1981;292(5819):154–156

Martin GR. Isolation of a pluripotent cell line derived from a mouse embryo. Cell 1981;292(5819):154–156

Yim RL, Lee JT, Bow CH, et al. A systematic review of the safety and efficacy of mesenchymal stem cells for disc degeneration: insights and future directions for regenerative therapeutics. Stem Cells Dev 2014;23(21):2553–2567

Wang Z, Perez-Terzic CM, Smith J, et al. Efficacy of intervertebral disc regeneration with stem cells—a systematic review and meta-analysis of animal controlled trials. Gene 2015;656(1):1–8

Rajpurkar R, Rishub MV, Dychenyche P, Vresilovic Bj, Shapiro IM. Phenotypic characteristics of the nucleus pulposus: expression of hyposa inducing factor-1, glucose transporter-1 and MPP-2. Cell Tissue Res 2002;308(3):401–407

Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksen G, Peterson L. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med 1994;331(14):889–895

Pittenger MF, Mackay AM, Beck SC, et al. Multipotentiality of adult human mesenchymal stem cells. Science 1999;284(5411):143–147

Evans MJ, Kaufman MH. Establishment in culture of pluripotential cell lines from mouse embryos. Nature 1981;292(5819):154–156

Martin GR. Isolation of a pluripotent cell line derived from a mouse embryo. Cell 1981;292(5819):154–156

Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126(4):663–676

Langer R, Vacanti JP. Tissue engineering. Science 1993;260(5110):920–926
Omlor GW, Fischer J, Kleinschmitt K, et al. Short-term follow-up of disc cell therapy in a porcine nucleotomy model with an albumin-hyaluronic hydrogel: in vivo and in vitro results of metabolic disc cell activity and implant distribution. Eur Spine J 2014;23(9):1837–1847

Leung VY, Aladin DM, Lv F, et al. Mesenchymal stem cells reduce intervertebral disc fibrosis and facilitate repair. Stem Cells 2014;32(8):2164–2177

Iwashina T, Mochida J, Sakai D, et al. Feasibility of using a human nucleus pulposus cell line as a cell source in cell transplantation therapy for intervertebral disc degeneration. Spine (Phil a Pa 1976) 2006;31(11):1177–1186

Hudson KD, Alimi M, Grunert P, Härtl R, Bonassar LJ. Recent advances in biological therapies for disc degeneration: tissue engineering of the annulus fibrosus, nucleus pulposus and whole intervertebral discs. Curr Opin Biotechnol 2013;24(3):872–879

Mizuno H, Roy AK, Zaporojan V, Vacanti CA, Ueda M, Bonassar LJ. Biomechanical and biochemical characterization of composite tissue-engineered intervertebral discs. Biomaterials 2006;27(3):362–370

Gebhard H, Bowles R, Dyke J, et al. Total disc replacement using a tissue-engineered intervertebral disc in vivo: new animal model and initial results. Evid Based Spine Care J 2010;1(2):62–66

James AR, Bowles RD, Gebhard HH, Bonassar LJ, Härtl R. Tissue-engineered total disc replacement: final outcomes of a murine caudal disc in vivo study. Evid Based Spine Care J 2011;2(4):55–56

Grunert P, Borde BH, Hudson KD, Macielak MR, Bonassar LJ, Härtl R. Annular repair using high-density collagen gel: a rat-tail in vivo model. Spine (Phil a Pa 1976) 2014;39(3):198–206

Moriguichi Y. Total disc replacement using tissue engineered intervertebral discs in an in vivo Beagle model. 2014 ORS Annual Meeting. Available at: http://www.ors.org/Transactions/61/0061.pdf. Accessed January 6, 2016

Elliott DM, Yerramallli CS, Beckstein JC, Boxberger JL, Johannessen W, Vresilovic EJ. The effect of relative needle diameter in puncture and sham injection animal models of degeneration. Spine (Phil a Pa 1976) 2008;33(6):588–596

Iatridis JC, Michalek AJ, Purmussur D, Korecki CL. Localized intervertebral disc injury leads to organ level changes in structure, cellularity, and biosynthesis. Cell Mol Bioeng 2009;2(3):437–447

Korecki CL, Costi JJ, Iatridis JC. Needle puncture injury affects intervertebral disc mechanics and biology in an organ culture model. Spine (Phil a Pa 1976) 2008;33(3):235–241

Hsieh AH, Hwang D, Ryan DA, Freeman AK, Kim H. Degenerative anular changes induced by puncture are associated with insufficiency of disc biomechanical function. Spine (Phil a Pa 1976) 2009;34(10):998–1005

Ahlgren BD, Lui W, Herbokwitz HN, Panjabi MM, Guiboux JP. Effect of annular repair on the healing strength of the intervertebral disc: a sheep model. Spine (Phil a Pa 1976) 2000;25(17):2165–2170

Chiang CJ, Cheng CK, Sun JS, Liao CJ, Wang YH, Tsuang YH. The effect of a new annular repair after discectomy in an intervertebral disc degeneration: an experimental study using a porcine spine model. Spine (Phil a Pa 1976) 2011;36(10):761–769

Bailey A, Araghi A, Blumenthal S, Huffman GV; Anular Repair Clinical Study Group. Prospective, multicenter, randomized, controlled study of annular repair in lumbar discectomy: two-year follow-up. Spine (Phil a Pa 2016) 2013;38(14):1161–1169

Nerurkar NL, Baker BM, Sen S, Wible EE, Elliott DM, Mauck RL. Nonfibrous biologic laminates replicate the form and function of the annulus fibrosus. Nat Mater 2009;8(12):986–992

Freeman BJ, Walters RM, Moore RJ, Fraser RD. Does intradiscal electrotherapy denervate and repair experimentally induced posterolateral annular tears in an animal model? Spine (Phil a Pa 1976) 2003;28(23):2602–2608

Wang YH, Kuo TF, Wang JL. The implantation of non-cell-based materials to prevent the recurrent disc herniation: an in vivo porcine model using quantitative discomannometry examination. Eur Spine J 2007;16(7):1021–1027

Ledet EH, Jeshuran W, Glennon JC, et al. Small intestinal submu cosa for anular defect closure: long-term response in an in vivo sheep model. Spine (Phil a Pa 1976) 2009;34(14):1457–1463

Oehme D, Ghosh P, Shimmmon S, et al. Mesenchymal progenitor cells combined with pentosan polysulfate mediating disc regeneration at the time of microdiscectomy: a preliminary study in an ovin model. J Neurosurg Spine 2014;20(6):657–669

Likhithapanichkul M, Dreischaf M, Illien-Junger S, et al. Fibrinogenpin adhesive hydrogel for annulus fibrosus repair: performance evaluation with large animal organ culture, in situ biomechanics, and in vivo degradation tests. Eur Cell Mater 2014;28:25–37, discussion 37–38

Hegewald AA, Medved F, Deng D, et al. Enhancing tissue repair in annulus fibrosus defects of the intervertebral disc: analysis of a bio-integrative annulus implant in an in-vivo ovine model. J Tissue Eng Regen Med 2015;9(4):405–414

Haufe SM, Mork AR. Intradiscal injection of hematopoietic stem cells in an attempt to rejuvenate the intervertebral discs. Stem Cells Dev 2006;15(1):136–137

Ruan D, He Q, Ding Y, Hou L, Li J, Luk JD. Intervertebral disc transplantation in the treatment of degenerative spine disease: a preliminary study. Lancet 2007;369(9566):993–999

Meisel HJ, Ganey T, Hutton WC, Libera J, Minkus Y, Alasevic O. Clinical experience in cell-based therapeutics: intervention and outcome. Eur Spine J 2006;15(Suppl 3):S397–500

Berlemann U, Schwarzenbach O. An injectable nucleus replacement as an adjunct to microdiscectomy: 2 year follow-up in a pilot clinical study. Eur Spine J 2009;18(11):1706–1712

Yoshikawa T, Ueda Y, Miyazaki K, Koiuzumi M, Takakura Y. Disc regeneration therapy using narrow mesenchymal cell transplantation: a report of two case studies. Spine (Phil a Pa 1976) 2010;35(11):E475–E480

Orozco L, Soler R, Morera C, Alberca M, Sánchez A, García-Sancho J. Intervertebral disc repair by autologous mesenchymal bone marrow cells: a pilot study. Transplantation 2011;92(7):822–828

Coric D, Pettine K, Sumich A, Boltes MO. Prospective study of disc repair with allogeneic chondrocytes presented at the 2012 Joint Spine Section Meeting. J Neurosurg Spine 2013;18(1):85–95

Pettine KA, Murphy MB, Suzuki RK, Sand TT. Percutaneous injection of autologous bone marrow concentrate cells significantly reduces lumbar discogenic pain through 12 months. Stem Cells 2015;33(3):146–156

Meisel HJ, Siodla V, Ganey T, Minkus Y, Hutton WC, Alasevic OJ. Clinical experience in cell-based therapeutics: disc chondrocyte transplantation A treatment for degenerated or damaged intervertebral disc. Biomol Eng 2007;24(1):5–21

Boyd LM, Carter AJ. Injectable biomaterials and vertebral end plate treatment for repair and regeneration of the intervertebral disc. Eur Spine J 2006;15(Suppl 3):S514–S521

Coric D. A study comparing the safety and effectiveness of cartilage cell injected into the lumbar disc as compared to a placebo. Available at: https://clinicaltrials.gov/ct2/show/NCT01771471. Accessed May 15, 2015

Brown R. Safety and preliminary efficacy study of mesenchymal precursor cells (MPCs) in subjects with lumbar back pain. Available at: https://clinicaltrials.gov/ct2/show/NCT012903677?term=mesenchymal+precursor+cells+in+subjects+with+chronic+discogenic+lumbar+b-ack+pain&rank=1. Accessed May 15, 2015

Francisco A. Treatment of degenerative disc disease with allogenic mesenchymal stem cells (MSV) (Disc_allo). 2015. Available at: https://clinicaltrials.gov/ct2/show/NCT01860417

Tai-Hyoung C. Autologous adipose tissue derived mesenchymal stem cells transplantation in patient with lumbar intervertebral
Biological Treatment Approaches for Degenerative Disk Disease

Moriguchi et al.

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.